Finance

E

Shares of Cyclacel Pharmaceuticals (CYCC) dropped as much as 75% on December 16, 2014 after the Data and Safety Monitoring Committee — DSMB — determined that the company’s drug known as sapacitabine would not reach its primary endpoint of survival in patients with AML — Acute Myeloid Leukemia. The Phase 3 trial known as SEAMLESS…

Play The Hot LendingClub IPO With These 3 ETFs

LendingClub (LC), the first peer-to-peer lending company, made a shining debut on the New York Stock Exchange last week. It raised $870 million in its IPO at a starting  price of $15, above its expected price range of $12–$14 (currently trading at $27.90). LendingClub in Focus LendingClub provides an online platform that connects borrowers with…

Will We Ever Kill The Bug? Testing A Vintage Investment Strategy

There is something very attractive about vintage items that just won’t die. They just keep coming back. Same philosophy but better up-to-date technology. It’s not just cars. It’s investment strategies, too. Vintage strategies are often simple, easy to execute and provide ample ‘out-of-sample’ data. In other words one can see how they performed in real…

Relief Bounce In Markets

Those who took advantage of markets at Fib levels were rewarded. However, this looked more a ‘dead cat’ style bounce than a genuine bottom forming low. This can of course change, and one thing I will want to see is narrow action near today’s high. Volume was a little light, but with Christmas fast approaching…

I’m Not Buying It–Not The Wall Street ‘Rip’, Nor The Keynesian Do...

First comes production. Then comes income. Spending and savings follow. All the rest is debt…….unless you believe in a magic Keynesian ether called “aggregate demand” and a blatant stab-in-the-dark called “potential GDP”. I don’t. So let’s start with a pretty startling contrast between two bellwether data trends since the pre-crisis peak in late 2007—debt versus production. Not…